GlassScriptPhysician profile
Peter K Kwofie
NPI 1124002118
$3,153.52
in general payments reported to CMS, 2019-2025
28 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $766 · 2021: $942 · 2022: $356 · 2023: $275 · 2024: $216 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $658 · Education: $33.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $657.64 |
| Education | $33.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $624.80 | 2019-2025 | Mounjaro, Jardiance |
| Novo Nordisk INC | $326.92 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $276.42 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $242.51 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $187.48 | 2020-2024 | Nuzyra |
| Glaxosmithkline, LLC. | $159.52 | 2019-2024 | Benlysta, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $147.51 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $146.58 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $137.04 | 2019-2023 | Livalo, Seglentis |
| Merck Sharp & Dohme LLC | $112.23 | 2019-2021 | |
| Astellas Pharma US INC | $99.95 | 2021 | |
| Insmed, INC. | $87.56 | 2019-2025 | Arikayce, Brinsupri |
| Bayer Healthcare Pharmaceuticals INC. | $81.86 | 2022-2025 | |
| Cipla USA INC. | $74.12 | 2022 | |
| Amarin Pharma, INC. | $59.93 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $54.38 | 2020-2021 | |
| Allergan, INC. | $47.32 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $45.51 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.32 | 2020-2021 | |
| Medicure Pharma INC. | $39.27 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $32.44 | 2024 | Airsupra |
| Medtronic, INC. | $31.18 | 2023 | Minimed 770g |
| Abbott Laboratories | $23.39 | 2024 | Freestyle Libre 3 |
| Ferring Pharmaceuticals INC. | $15.54 | 2025 | Rebyota |
| Currax Pharmaceuticals LLC | $15.41 | 2022 | |
| Dexcom, INC. | $15.17 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.94 | 2019 | |
| Forte Bio-Pharma LLC | $12.22 | 2020-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Kwofie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.